<?xml version="1.0" encoding="UTF-8"?>
<ref id="B246-pharmaceuticals-14-00381">
 <label>246.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wynn</surname>
    <given-names>G.H.</given-names>
   </name>
   <name>
    <surname>Zapor</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>B.H.</given-names>
   </name>
   <name>
    <surname>Wortmann</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Oesterheld</surname>
    <given-names>J.R.</given-names>
   </name>
   <name>
    <surname>Armstrong</surname>
    <given-names>S.C.</given-names>
   </name>
   <name>
    <surname>Cozza</surname>
    <given-names>K.L.</given-names>
   </name>
  </person-group>
  <article-title>Antiretrovirals, Part 1: Overview, History, and Focus on Protease Inhibitors</article-title>
  <source>Psychosomatics</source>
  <year>2004</year>
  <volume>45</volume>
  <fpage>262</fpage>
  <lpage>270</lpage>
  <pub-id pub-id-type="doi">10.1176/appi.psy.45.3.262</pub-id>
  <pub-id pub-id-type="pmid">15123854</pub-id>
 </element-citation>
</ref>
